Progyny (PGNY) Scheduled to Post Quarterly Earnings on Tuesday

Progyny (NASDAQ:PGNY) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, August 6th. Analysts expect Progyny to post earnings of $0.36 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, May 9th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. Progyny had a return on equity of 11.61% and a net margin of 5.53%. The company had revenue of $278.08 million during the quarter, compared to analysts’ expectations of $289.41 million. During the same period in the prior year, the company earned $0.18 EPS. Progyny’s revenue was up 7.6% compared to the same quarter last year. On average, analysts expect Progyny to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Progyny Stock Up 1.4 %

Progyny stock traded up $0.42 during trading hours on Tuesday, hitting $29.44. The stock had a trading volume of 91,538 shares, compared to its average volume of 947,006. The business’s 50 day simple moving average is $27.64 and its 200-day simple moving average is $32.92. Progyny has a one year low of $23.90 and a one year high of $44.95. The stock has a market cap of $2.80 billion, a price-to-earnings ratio of 47.57, a P/E/G ratio of 1.89 and a beta of 1.46.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Canaccord Genuity Group cut their target price on shares of Progyny from $46.00 to $37.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. KeyCorp lowered Progyny from an “overweight” rating to a “sector weight” rating in a research report on Friday, May 10th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $48.00 price target on shares of Progyny in a research report on Thursday, May 16th. BTIG Research reduced their target price on Progyny from $50.00 to $41.00 and set a “buy” rating on the stock in a report on Friday, May 10th. Finally, Barclays lowered their price target on shares of Progyny from $48.00 to $30.00 and set an “overweight” rating for the company in a report on Monday, May 13th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.40.

Insider Activity at Progyny

In other news, President Michael E. Sturmer sold 4,515 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $31.95, for a total transaction of $144,254.25. Following the completion of the sale, the president now owns 380,038 shares in the company, valued at $12,142,214.10. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, President Michael E. Sturmer sold 4,515 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $31.95, for a total value of $144,254.25. Following the transaction, the president now directly owns 380,038 shares in the company, valued at approximately $12,142,214.10. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, President Michael E. Sturmer sold 9,030 shares of the business’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $30.00, for a total transaction of $270,900.00. Following the sale, the president now owns 362,583 shares of the company’s stock, valued at approximately $10,877,490. The disclosure for this sale can be found here. Insiders sold 15,007 shares of company stock valued at $456,660 in the last three months. Corporate insiders own 12.30% of the company’s stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.